Trial
NCT02536300
Dose Optimization Study of Idelalisib in Follicular Lymphoma
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Gilead Sciences
Collaborators
—
Condition
Follicular Lymphoma
Intervention
Idelalisib
Why stopped
Gilead has made the decision to close the study due to enrollment challenges
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-08-14